Other Conditions

Saligan et al. (2016) found that a double-blind, placebo-controlled, crossover study in bipolar disorder showed ketamine significantly reduced fatigue scores compared to placebo.

 

Kopra et al. (2021) conducted a systematic review on the effects of ketamine on inflammation and kynurenine pathway in depression. Their findings suggest that ketamine has anti-inflammatory effects in some depressed patients. Future research should examine central nervous system markers and clinical relevance of these changes. Boldrini et al. (2021) discussed how COVID-19 affects the brain, with some patients experiencing cognitive deficits, anxiety, depression, and seizures. The understanding of COVID-19 brain damage could lead to interventions to reduce neuropsychiatric symptoms, which may include ketamine therapy as an NMDA receptor antagonist.

 

Smalheiser (2020) suggested that ketamine therapy could be a potential treatment for Alzheimer's disease, based on its similar pharmacologic profile to memantine, one of the most commonly prescribed drugs for Alzheimer's patients. The existing literature provides a strong scientific rationale for testing the precognitive effects of ketamine in Alzheimer's patients.

​

See for more literature on Depression, Anxiety, Substance Abuse, Other Mental Health Conditions, Chronic Pain.

​

Other useful articles

• Ketamine in COVID‐19 patients: Thinking out of the box (2020)

• Psychedelics as a novel approach to treating autoimmune conditions (2020)

• Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View (2021)